OCGN Ocugen Inc

Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results

Ocugen To Host Conference Call on Friday, August 5 at 8:30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results

MALVERN, Pa., July 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel cell and gene therapies and vaccines, today announced that it will host a conference call and simultaneuous webcast to discuss the Company’s second quarter 2022 financial results and provide a business update at 8:30 a.m. ET on Friday, August 5, 2022.

Ocugen will issue a pre-market earnings announcement on the same day. Attendees are invited to participate on the call using the following details:

Dial-in Numbers: (800) 715-9871 for U.S. callers and (646) 307-1963 for international callers

Conference ID: 7036957

Webcast: Available on the section of the Ocugen

A replay of the call and archived webcast will be available for approximately 45 days following the event on the Ocugen .

About Ocugen, Inc.



Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. 

Discover more at  and follow us on  and 

Cautionary Note on Forward-Looking Statements



This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

Contacts:

Tiffany Hamilton

Head of Communications



EN
29/07/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ocugen Inc

 PRESS RELEASE

Ocugen To Present at BIO International Convention 2025

Ocugen To Present at BIO International Convention 2025 MALVERN, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present at the 2025 BIO International Convention at the Boston Convention & Exhibition Center from June 16-19, 2025. During the conference, Ocugen’s leadership team will host meetings with potential partners and pharmaceutical executives to explore opportunities for the Company’s novel modifier gene therapy platform targ...

 PRESS RELEASE

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License o...

Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea Upfront fees and near-term development milestone payments totaling up to $11 millionSales milestones of $150 million or more in first 10 years of commercializationRoyalties equaling 25% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding...

 PRESS RELEASE

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410...

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United States Food and Drug Administration (U.S. FDA) has granted Rare Pediatric Disease Designation (RPDD) for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3. Previou...

 PRESS RELEASE

Ocugen Provides Business Update with First Quarter 2025 Financial Resu...

Ocugen Provides Business Update with First Quarter 2025 Financial Results Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease mid- 2025 MALVERN, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported first quarter 2025 financial resu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch